New medication more potent, longer lasting than morphine

Jan 04, 2011

(PhysOrg.com) -- A little-known morphinelike drug is potentially more potent, longer lasting and less likely to cause constipation than standard morphine, a study led by a Loyola University Health System anesthesiologist has found.

The drug, morphine-6-0-sulfate, has a similar to standard . Dr. Joseph Holtman Jr. and colleagues reported that a study they performed in rats "demonstrated potential clinical advantages of morphine-6-0-sulfate compared to morphine."

Holtman is first author of the study, published in the December 2010 issue of the European Journal of Pharmacology.

Holtman is medical director of Loyola's Specialty Service and a professor in the departments of Anesthesiology and and Therapeutics of Loyola University Chicago Stritch School of Medicine. He directed the study while he was at the University of Kentucky’s College of Medicine. He joined Loyola on March 1, 2010.

Opioids, such as morphine, oxycodone and hydrocodone, are standard drugs for treating moderate to severe pain, including cancer pain. But these drugs can have significant side effects, including constipation, nausea, vomiting, drowsiness, cognitive dysfunction and slowed breathing and heart rates. And while opioids work well for conditions such as back pain and post-operative pain, the drugs are less effective against neuropathic pain, such as tingling, burning or shooting pain.

Constipation is a common side effect of morphine and can be so uncomfortable that some patients limit their use of the drug. Doctors typically do not discharge surgery patients until they have had a bowel movement and this can extend hospital stays.

Holtman and colleagues tested standard morphine and morphine-6-0-sulfate on rats. The animals received the drugs three ways -- by mouth, by IV and by injection into the space surrounding the spinal cord.

The rats underwent several well-established tests to determine their sensitivity to pain. In one such test, researchers focused a very warm light beam on the tail and measured how long it took for the rat to flick the tail.

In this tail-flick test, morphine-6-0-sulfate was 10 times more potent than standard morphine when administered in the space surrounding the spinal cord, five times more potent when administered by IV and two times more potent when given by mouth. Morphine-6-0-sulfate maintained its maximum effect for three hours, compared with 1½ hours for standard morphine. And it took rats 25 days to build tolerance to morphine-6-0-sulfate, compared with 10 days with standard morphine.

Morphine-6-0-sulfate also was more potent than standard morphine for neuropathic and inflammatory pain.

Researchers found that morphine-6-0-sulfate could cause constipation, but only at doses 10 to 20 times higher than the effective doses.

The findings suggest that morphine-6-0-sulfate "may be an interesting potential drug for further study," Holtman and colleagues wrote.

Explore further: Rapivab approved to help treat flu

Provided by Loyola University

3.5 /5 (6 votes)
add to favorites email to friend print save as pdf

Related Stories

Morphine blocks tumor growth

Jul 28, 2010

Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the ...

Morphine kills pain -- not patients

Mar 21, 2007

Many people, including health care workers, believe that morphine is a lethal drug that causes death when used to control pain for a patient who is dying. That is a misconception according to new research published in the ...

Researchers find new target to improve pain management

Sep 07, 2010

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic ...

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

14 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments : 4

Adjust slider to filter visible comments by rank

Display comments: newest first

Quantum_Conundrum
2.3 / 5 (3) Jan 04, 2011
...and of course, they'll just charge 10 to 20 times more to administer this drug.
kshultz222_yahoo_com
5 / 5 (1) Jan 04, 2011
The biggest problem is that it will take 10 - 20 years to get it on the market.
ormondotvos
5 / 5 (1) Jan 04, 2011
Well, how hard is it to synthesize?

Big market to constipated chronic pain sufferers ... sell it on the street outside medical cannabis clinics.
wileruilaer
not rated yet Jan 05, 2011
I wonder if addictiveness is also 2-10 times higher. If so, this drug would probably not be very useful for the majority of pain sufferers, but would mostly be used the same way we use the more potent opioids today, in specialized surgical, oncological, neurological and palliative settings where addiction is already considered a secondary problem. In those cases, reduced side effects would be welcome. If, however, this drug also exhibits significantly less addictiveness - this might be a very welcome addition in the arsenal of primary health care pain relief.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.